Page last updated: 2024-09-05

sorafenib and topotecan

sorafenib has been researched along with topotecan in 8 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(topotecan)
Trials
(topotecan)
Recent Studies (post-2010) (topotecan)
6,5207305,2512,392626792

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)topotecan (IC50)
Cytochrome P450 3A4Homo sapiens (human)1.5211
DNA topoisomerase 1Homo sapiens (human)0.8525
DNA topoisomerase 2-alphaHomo sapiens (human)0.605
DNA topoisomerase 2-betaHomo sapiens (human)0.605
Hypoxia-inducible factor 1-alphaHomo sapiens (human)0.06
Multidrug and toxin extrusion protein 2Homo sapiens (human)8.6
Multidrug and toxin extrusion protein 1Homo sapiens (human)1.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.17

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Amen, Y; El-Sayed, MA; Kitamura, M; Okauchi, T; Othman, DIA; Selim, KB; Shimizu, K; Tantawy, AS1
Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E1
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ1
Braicu, EI; Chekerov, R; De Gregorio, N; du Bois, A; El-Balat, A; Fridrich, C; Harter, P; Hilpert, F; Krabisch, P; Lorenz, R; Lueck, HJ; Mahner, S; Markmann, S; Oskay-Oezcelik, G; Potenberg, J; Richter, R; Schmidt, M; Sehouli, J1
Corrado, G; Ferrandina, G1

Reviews

1 review(s) available for sorafenib and topotecan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

3 trial(s) available for sorafenib and topotecan

ArticleYear
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan

2011
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult

2015
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Germany; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Time Factors; Topoisomerase I Inhibitors; Topotecan

2018

Other Studies

4 other study(ies) available for sorafenib and topotecan

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives.
    Bioorganic & medicinal chemistry, 2019, 10-01, Volume: 27, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Caspase 9; Cell Proliferation; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Molecular Structure; Quinolines; Structure-Activity Relationship; Thiophenes

2019
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Molecular pharmaceutics, 2011, Apr-04, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Cells, Cultured; Dogs; Humans; Indoles; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Topoisomerase I Inhibitors; Topotecan

2011
Treatment of platinum refractory or resistant ovarian cancer.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan

2018